Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.51 |
| ▸ | GSK3B | P49841 | 4/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.51 |
| ▸ | CLK2 | P49760 | 3/20 | 0.51 |
| ▸ | PRKG2 | Q13237 | 3/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | PRKX | P51817 | 2/20 | 0.51 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.51 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.51 |
| ▸ | EEF2K | O00418 | 1/20 | 0.51 |
| ▸ | NEK4 | P51957 | 1/20 | 0.51 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.51 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.46 |
| ▸ | PRKACA | P17612 | 3/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228644 | 0.91 | ROCK2 (0.53) | ROCK2ROCK1GSK3BCLK4CLK2 | |
| SCHEMBL4123853 | 0.83 | ROCK2 (0.51) | ROCK2ROCK1POLBMEN1KMT2A | |
| SCHEMBL4116191 | 0.79 | CNR1 (0.54) | ROCK2POLBMEN1KMT2ANPC1 | |
| SCHEMBL13925271 | 0.77 | MAPT (0.43) | ROCK2ROCK1GSK3BCLK4CLK2 | |
| SCHEMBL1229259 | 0.75 | ROCK1 (0.54) | ROCK2ROCK1GSK3BCLK4CLK2 | |
| SCHEMBL922192 | 0.73 | ANO1 (0.46) | MAP2K4 | |
| SCHEMBL2259660 | 0.71 | FPR1 (0.40) | MAP2K4 | |
| SCHEMBL4911196 | 0.71 | MEN1 (0.55) | ROCK2ROCK1GSK3BCLK4CLK2 | |
| SCHEMBL1229231 | 0.71 | POLB (0.44) | ROCK2ROCK1GSK3BCLK4CLK2 | |
| SCHEMBL1229463 | 0.71 | ROCK2 (0.51) | ROCK2ROCK1GSK3BCLK4CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-01-17 | — | — | US | claimed |
| EP-2459184-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | The Brigham and Women's Hospital, Inc. (US) | 2012-06-06 | — | — | EP | claimed |
| WO-2011014775-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | claimed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | claimed |
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| EP-2459184-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | The Brigham and Women's Hospital, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014775-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017188-A1 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES | SGK1, SGK3, SGK2 | ROCK2 793/4885ROCK1 523/4885GSK3B 108/4885 |
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | CHEK2, CHEK1, SIK2 | ROCK2 1094/4885ROCK1 979/4885GSK3B 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.